ScholarIQanswers from OpenAlex & ORCID
Suzanne L. Topalian
ResearcherPublications, citations & collaboration network
Suzanne L. Topalian is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Suzanne L. Topalian have?
ScholarIQindexed works
Suzanne L. Topalian has 360 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Suzanne L. Topalian have?
ScholarIQcitation count
Suzanne L. Topalian has 98,037 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Suzanne L. Topalian?
ScholarIQh-index
Suzanne L. Topalian has an h-index of 101 in OpenAlex.
What is the i10-index of Suzanne L. Topalian?
ScholarIQi10-index
Suzanne L. Topalian has an i10-index of 213 in OpenAlex.
What is the ORCID of Suzanne L. Topalian?
ScholarIQorcid
The ORCID for Suzanne L. Topalian is on the source record.
What is the OpenAlex record for Suzanne L. Topalian?
ScholarIQopenalex
The OpenAlex for Suzanne L. Topalian is on the source record.
What are the most-cited papers on Suzanne L. Topalian?
ScholarIQmost cited works
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure–Kunkel, Shruti Agrawal, D. G. McDonald, Georgia Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, Wen-Jen Hwu, Suzanne L. Topalian, Patrick Hwu, Charles G. Drake, Luis H. Camacho, John Kauh, Kunle Odunsi, Henry C. Pitot, Omid Hamid, Shailender Bhatia, Renato Martins, Keith D. Eaton, Shuming Chen, Theresa M. Salay, Suresh Alaparthy, Joseph F. Grosso, Alan J. Korman, Susan Parker, Shruti Agrawal, S. Goldberg, Drew M. Pardoll, Ashok Gupta, Jon M. Wigginton
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer, Charles G. Drake, Ira Wollner, John D. Powderly, Joel Picus, William H. Sharfman, Elizabeth Stankevich, Alice Pons, Theresa M. Salay, Tracee L. McMiller, Marta M. Gilson, Changyu Wang, Mark Selby, Janis M. Taube, Robert A. Anders, Lieping Chen, Alan J. Korman, Drew M. Pardoll, Israel Lowy, Suzanne L. Topalian
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Mark E. Dudley, John R. Wunderlich, Paul F. Robbins, James Chih‐Hsin Yang, Patrick Hwu, Douglas J. Schwartzentruber, Suzanne L. Topalian, Richard M. Sherry, Nicholas P. Restifo, Amy M. Hubicki, Michael R. Robinson, Mark Raffeld, Paul H. Duray, Claudia A. Seipp, Linda Rogers-Freezer, Kathleen E. Morton, Sharon Mavroukakis, Donald E. White, Steven A. Rosenberg
A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
James Chih‐Hsin Yang, Leah Haworth, Richard M. Sherry, Patrick Hwu, Douglas J. Schwartzentruber, Suzanne L. Topalian, Seth M. Steinberg, Helen X. Chen, Steven A. Rosenberg